• Molecular NameTeriparatide
  • SynonymhPTH 1-34; PTH1-34 nasal spray; synthetic human parathyroid hormone 1-34; ViaDerm hPTH 1-34; ViaDerm-hPTH (1-34)
  • Weight4117.79
  • Drugbank_IDDB06285
  • ACS_NO52232-67-4
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)N/A
  • pkaN/A
  • LogD (pH=7, predicted)N/A
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)N/A
  • LogSw (predicted, AB/LogsW2.0)N/A
  • Sw (mg/ml) (predicted, ACD/Labs)N/A
  • No.of HBond DonorsN/A
  • No.of HBond AcceptorsN/A
  • No.of Rotatable BondsN/A
  • TPSAN/A
  • StatusFDA approved
  • AdministrationSubQ
  • PharmacologyA recombinant form of parathyroid hormone, used in the treatment of some forms of osteoporosis.
  • Absorption_valueN/A
  • Absorption (description)Bioavailability is 95% following subcutaneous injection.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)0.12 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (nonspecific proteolysis)
  • Half lifeSubQ: 1 hour
  • ExcretionRenal (metabolites)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityEffects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A